Bolt Biotherapeutics Inc BOLT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$6.33 down $0.05, 0.78% on Nov 6
Last price · Previous close $6.38
- Market cap
- At the last price
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$6.33down $0.05, 0.78%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$6.38Nov 5
- Volume170.37KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume692.42KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.10 to $7.78; now $6.33
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the last price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
BOLT beat the S&P 500 in 4 of 6 periods.
| Period | BOLT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BOLT: up 80.3% S&P 500: down 5.6% | BOLT beat the S&P 500 by 85.9 percentage points Beat |
| 3M | BOLT: up 63.6% S&P 500: down 4.1% | BOLT beat the S&P 500 by 67.7 percentage points Beat |
| YTD | BOLT: up 15.8% S&P 500: up 8.7% | BOLT beat the S&P 500 by 7.1 percentage points Beat |
| 1Y | BOLT: up 32.4% S&P 500: up 10.9% | BOLT beat the S&P 500 by 21.5 percentage points Beat |
| Long term | ||
| 3Y | BOLT: down 68.4% S&P 500: up 75.0% −31.9% vs +20.5% a year | BOLT trailed the S&P 500 by 143.4 percentage points Trailed |
| 5Y | BOLT: down 97.3% S&P 500: up 67.8% −51.6% vs +10.9% a year | BOLT trailed the S&P 500 by 165.1 percentage points Trailed |
$10,000 invested in BOLT 5 years ago (Nov 5, 2021) would be worth about $266 as of , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
BOLT beat the S&P 500 in 4 of 6 periods.
| Period | BOLT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BOLT: up 80.3% S&P 500: down 5.6% | BOLT beat the S&P 500 by 85.9 percentage points Beat |
| 3M | BOLT: up 63.6% S&P 500: down 4.3% | BOLT beat the S&P 500 by 67.9 percentage points Beat |
| YTD | BOLT: up 15.8% S&P 500: up 7.8% | BOLT beat the S&P 500 by 8.0 percentage points Beat |
| 1Y | BOLT: up 32.4% S&P 500: up 9.7% | BOLT beat the S&P 500 by 22.7 percentage points Beat |
| Long term | ||
| 3Y | BOLT: down 68.4% S&P 500: up 68.8% −31.9% vs +19.1% a year | BOLT trailed the S&P 500 by 137.2 percentage points Trailed |
| 5Y | BOLT: down 97.3% S&P 500: up 56.9% −51.6% vs +9.4% a year | BOLT trailed the S&P 500 by 154.2 percentage points Trailed |
$10,000 invested in BOLT 5 years ago (Nov 5, 2021) would be worth about $266 as of , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$798.60
Closing high on . Now 99.2% below that record.
Split-adjusted daily closes since Feb 5, 2021.
Stock splits
1
1-for-20 on . Share counts adjust after each split.
Valuation
Financials
About Bolt Biotherapeutics Inc
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody ISACs in strategic collaborations with leading biopharmaceutical companies.
- Sector
- Industry
- Headquarters
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
BOLT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
BOLT stock FAQ
What is BOLT stock’s price today?
Bolt Biotherapeutics (BOLT) traded at $6.33 as of , down $0.05 (0.78%) from the previous close of $6.38. Over the past 52 weeks it has traded between $3.10 and $7.78.
If you invested $1,000 in BOLT 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in BOLT on would be worth about $27 as of , a total return of −97.3%. The same $1,000 would be worth $1,324 if invested one year ago. Past performance doesn’t predict future returns.
Does BOLT pay a dividend?
Bolt Biotherapeutics hasn’t paid a dividend in the last twelve months.
What is BOLT’s 52-week high and low?
Over the past 52 weeks BOLT has traded as low as $3.10 and as high as $7.78. At $6.33 as of , it is 18.6% below that high and 104.2% above the low.
What is BOLT’s all-time high?
BOLT’s highest closing price was $798.60 on , adjusted for stock splits. At $6.33 as of , it is 99.2% below that record.
Has BOLT stock ever split?
Yes, once: 1-for-20 on .
How has BOLT stock performed?
Including dividends and measured to the last price on , BOLT has returned +15.8% so far this year and +32.4% over the past year, and −97.3% over five years (−51.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What exchange does BOLT trade on?
Bolt Biotherapeutics trades on the Nasdaq under the ticker symbol BOLT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.